Atomera Inc — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Atomera reported Q2 2026 net loss of $6.3M ($0.17/share) vs. $5.0M loss in Q2 2025. Cash and short-term investments totaled $38.4M as of June 30, 2026, up from $19.2M at year-end 2025, funded by equity issuance (39.0M shares outstanding vs. 32.4M at Dec 31, 2025). Company announced technical breakthrough in GaN-on-Silicon RF applications with 1000X lower harmonic distortion than controls. Revenue remains minimal at $169K for H1 2026.
Why this rating
Cash raise (~$19M net) is material but typical for pre-revenue biotech-like licensor. Tech milestone is positive but unmonetized. Losses accelerating; runway ~3 years. No customer deals announced; early-stage risk unchanged.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.